TSE:CPH - Cipher Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$2.20 -0.01 (-0.45 %)
(As of 01/21/2019 12:43 PM ET)
Previous CloseC$2.21
Today's RangeC$2.15 - C$2.21
52-Week RangeC$1.62 - C$5.28
Volume2,766 shs
Average Volume62,153 shs
Market CapitalizationN/A
P/E Ratio10.85
Dividend YieldN/A
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$28.66 million
Cash FlowC$0.37 per share
Book ValueC$0.96 per share



OptionableNot Optionable

Cipher Pharmaceuticals (TSE:CPH) Frequently Asked Questions

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (TSE:CPH) released its earnings results on Wednesday, November, 7th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by $0.08. The company earned $6.31 million during the quarter, compared to analyst estimates of $8.60 million. View Cipher Pharmaceuticals' Earnings History.

When is Cipher Pharmaceuticals' next earnings date?

Cipher Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Cipher Pharmaceuticals.

What price target have analysts set for CPH?

1 brokers have issued twelve-month target prices for Cipher Pharmaceuticals' stock. Their forecasts range from C$4.25 to C$4.25. On average, they anticipate Cipher Pharmaceuticals' share price to reach C$4.25 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for Cipher Pharmaceuticals.

What is the consensus analysts' recommendation for Cipher Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

Media headlines about CPH stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cipher Pharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 50)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs
  • Mr. Michael Milloy, VP of Canadian Commercial Operations

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPH stock can currently be purchased for approximately C$2.20.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is http://www.cipherpharma.com/.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.

MarketBeat Community Rating for Cipher Pharmaceuticals (TSE CPH)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel